drugset / Trial / NCT00835848

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

NCT00835848

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy. Investigations both ex vivo and in vivo suggest that a gut derived hormone, Glucagon-Like-Peptide-1 (GLP-1), is able to reduce reperfusioninjury after myocardial ischemia. Results from our own laboratory have shown a marked reduction in infarct size when rat hearts in a Langendorf preparation were exposed to the GLP-1 analogue, exendin-4. The investigators want to investigate to what extent this effect can be translated to humans in the setting of acute STEMI treated with primary PCI when evalutaed by cardiac magnetic resonance imaging.

Timeline

Start
2009-01
Primary completion
2009-12
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide 25 ug Intravenous

Indications